CDK-IN-2

• Description:

  CDK-IN-2 is a specific CDK9 inhibitor with an IC50 of less than 8 nM. CDK-IN-2 reduces the phosphorylation level of H3S10. CDK-IN-2 decreases the transition rate of spermatocytes from prophase to metaphase I[1][2].

• Product Name Alternative:

  CDK inhibitor II

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/CDK-IN-2.html

• Concentration:

  10mM

• Purity:

  99.27

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  FC1=CC (C2=CC (NC ([C@H]3CNCCC3) =O) =NC=C2Cl) =C (C=C1) OC

• Molecular Formula:

  C18H19ClFN3O2

• Molecular Weight:

  363.81

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Keith B Pfister, et al. Heteroaryl compounds as kinase inhibitors. 2011, WO2011026917A1.|[2]Li H, et al. Global phosphoproteomic analysis identified key kinases regulating male meiosis in mouse. Cell Mol Life Sci. 2022 Aug 5;79 (8) :467.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK9

• CAS Number:

  1269815-17-9